Group 1 - The core point of the article is that Yangpu Medical reported a decline in revenue for the third quarter of 2025, while net profit saw a significant increase year-on-year [1] Group 2 - In the third quarter of 2025, the company achieved operating revenue of 118,274,679.35 yuan, representing a year-on-year decrease of 7.82% [1] - The net profit attributable to shareholders of the listed company was 8,777,532.54 yuan, showing a year-on-year growth of 123.57% [1]

Group 1 - The core point of the article is that Yangpu Medical (SZ 300030) held its 16th meeting of the 6th board of directors on October 27, 2025, to review the Q3 2025 report and other documents [1] - For the year 2024, Yangpu Medical's revenue composition is 99.18% from industrial operations and 0.82% from financing leasing [1] - As of the report date, Yangpu Medical has a market capitalization of 2.5 billion yuan [1]

Core Viewpoint - Yangpu Medical (300030.SZ) reported a decline in revenue for the first three quarters of 2025, while net profit showed significant growth [1] Financial Performance - The company's operating revenue for the first three quarters was 349 million yuan, a year-on-year decrease of 17.14% [1] - Net profit attributable to shareholders was 24.04 million yuan, reflecting a year-on-year increase of 156.55% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 30.36 million yuan, representing a year-on-year growth of 325.04% [1] - Basic earnings per share were 0.08 yuan [1]

阳普医疗科技股份有限公司 关于披露 2025 年第三季度报告的提示性公告 证券代码：300030 证券简称：阳普医疗 公告编号：2025-046 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 10 月 27 日 为使投资者全面了解本公司的经营成果、财务状况及未来发展规划，公司 《2025 年第三季度报告》将于 2025 年 10 月 28 日在中国证监会指定的创业板信 息披露网站巨潮资讯网（http://www.cninfo.com.cn）披露，敬请投资者注意查 阅。 特此公告。 阳普医疗科技股份有限公司董事会 2025 年 10 月 27 日，阳普医疗科技股份有限公司（以下简称"公司"）召开 了第六届董事会第十六次会议，审议通过了《2025 年第三季度报告》。 ...

证券代码：300030 证券简称：阳普医疗 公告编号：2025-045 阳普医疗科技股份有限公司 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票。 特此公告。 阳普医疗科技股份有限公司监事会 2025 年 10 月 27 日 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 阳普医疗科技股份有限公司（以下简称"公司"）第六届监事会第十四次会 议（以下简称"本次会议"）通知已于 2025 年 10 月 20 日以电子邮件方式送达全 体监事。本次会议于 2025 年 10 月 27 日在公司会议室以现场与通讯相结合的方式 召开。本次会议应到监事 3 人，实到监事 3 人，公司高级管理人员列席了本次会 议。本次会议的内容以及召集、召开的方式、程序均符合《公司法》和《公司章 程》的规定。本次会议由监事会主席方秋鹏先生主持。与会监事经过充分的讨论， 通过以下决议： 一、审议通过《2025 年第三季度报告》 公司监事会在全面审核和了解公司 2025 年第三季度报告后，认为公司 2025 年第三季度报告真实、准确、完整地反映了公司的实际经营状况和经营成果，认 为其陈 ...

证券代码：300030 证券简称：阳普医疗 公告编号：2025-044 阳普医疗科技股份有限公司 第六届董事会第十六次会议决议公告 2025 年 10 月 27 日 公司董事会在全面审核和了解公司 2025 年第三季度报告后，认为公司 2025 年第三季度报告真实、准确、完整地反映了公司的实际经营状况和经营成果，认 为其陈述事项真实、准确、完整，不存在应披露而未披露事项，不存在任何虚假 记载、误导性陈述或者重大遗漏。 《2025 年第三季度报告》（公告编号：2025-047）详见中国证监会指定的创 业板信息披露网站巨潮资讯网。 本议案提交董事会审议前已经公司董事会审计委员会审议通过。 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 特此公告。 阳普医疗科技股份有限公司董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 阳普医疗科技股份有限公司（以下简称"公司"）第六届董事会第十六次会 议（以下简称"本次会议"）通知已于 2025 年 10 月 20 日以电子邮件方式送达全 体董事。本次会议于 2025 年 10 月 27 日在公司会议室以现场与 ...

Financial Performance - Q3 2025 revenue was CNY 118,274,679.35, a decrease of 7.82% year-over-year, while year-to-date revenue reached CNY 349,231,193.17, down 17.14% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2025 was CNY 8,777,532.54, an increase of 123.57% year-over-year, with year-to-date net profit at CNY 24,044,095.67, up 156.55%[5] - The net profit excluding non-recurring items for Q3 2025 was CNY 15,177,917.20, a significant increase of 423.96% year-over-year, while year-to-date it was CNY 30,357,702.81, up 325.04%[5] - Total operating revenue for Q3 2025 was CNY 349,231,193.17, a decrease of 17.1% from CNY 421,468,424.66 in the same period last year[29] - Total operating costs for Q3 2025 were CNY 329,782,171.95, down 20.4% from CNY 413,928,591.21 in the previous year[29] - Net profit for Q3 2025 was CNY 23,445,300.50, compared to a net loss of CNY 44,632,335.57 in Q3 2024[30] - The company reported a gross profit margin of approximately 5.5% in Q3 2025, compared to a negative margin in the same quarter last year[30] Cash Flow and Assets - Cash flow from operating activities for the year-to-date period was CNY 71,345,913.50, an increase of 66.73%[5] - Cash flow from operating activities decreased by 45.21% to ¥5,479,561.18, due to a reduction in government subsidies and project guarantee recoveries[15] - Cash flow from investing activities showed a net outflow of ¥44,586,782.84, a significant increase of 276.57% compared to the previous period[16] - Cash and cash equivalents decreased by 1,765.19% to -¥130,310,349.72, primarily due to repayment of bank loans using internal funds[16] - The company's cash and cash equivalents decreased from CNY 247,949,011.09 to CNY 117,638,671.25, representing a decline of approximately 52.6%[27] - The ending balance of cash and cash equivalents was $117,020,731.28, down from $219,220,309.59[33] Investments and Income - The company recognized an investment income increase of CNY 31,291,100.00 from Shenzhen Yanghe Biomedical Industry Investment Co., Ltd. compared to the previous year[10] - Investment income increased by 244.16% to ¥18,710,906.35, reflecting a rise in fair value confirmation of investments[14] - Total profit rose by 167.56% to ¥27,926,751.64, driven by increased investment income and reduced losses from fair value changes of associates[14] - Cash received from investment income was $24,692,839.59, significantly higher than $1,614,986.41 in the previous period[33] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 28,504, with no preferred shareholders having restored voting rights[18] - The largest shareholder, Deng Guanhua, holds 15.91% of shares, with 36,895,916 shares pledged[18] - The total number of restricted shares decreased from 49,194,555 to 36,895,916 due to the release of shares held by executives[20] Cost Management and Efficiency - The company plans to continue focusing on cost control and efficiency improvements to mitigate the impact of declining revenues[10] - The company closed its wholly-owned subsidiary Guangzhou Ruida Medical Equipment Co., Ltd. as part of cost reduction efforts[23] - Financial expenses for the year-to-date period were CNY 3,213,416.02, down 58.46% compared to the previous year, primarily due to reduced interest expenses[13] Research and Development - The company has made significant investments in R&D to enhance product offerings and market competitiveness[22] - Research and development expenses for Q3 2025 were CNY 17,942,654.55, down 23.2% from CNY 23,376,301.59 in the same quarter last year[29] Asset Management - Total assets as of September 30, 2025, were CNY 1,079,746,419.77, a decrease of 13.21% from the end of the previous year[5] - The total assets decreased to CNY 1,079,746,419.77 from CNY 1,244,146,915.63, reflecting a decline of 13.2% year-over-year[29] - Total liabilities decreased to CNY 415,452,132.33 from CNY 600,282,029.67, a reduction of 30.7% compared to the previous year[29] - The company reported a total non-current asset balance of CNY 1,200,000,000.00 as of the end of the reporting period[27] Business Development - The company has established a joint venture named "联合生命" focusing on cell therapy and high-end health management, with operations commencing in the Hengqin area[25] - The company participated in several high-profile academic exchanges and exhibitions, showcasing key products like the specimen management system and intelligent blood collection management system[22] - The company aims to expand its localized service network, receiving high recognition from industry peers during recent conferences[22]

Core Viewpoint - Yangpu Medical's stock price has shown a significant increase of 42.21% year-to-date, indicating strong market performance despite recent fluctuations [2]. Company Overview - Yangpu Medical Technology Co., Ltd. was established on August 19, 1996, and listed on December 25, 2009. The company is located in Zhuhai, Guangdong Province, and primarily provides technical solutions, products, and services for clinical testing laboratories and clinical care [2]. - The company's revenue composition includes: vacuum blood collection systems (66.48%), reagents (12.23%), software products and services (10.03%), testing services (5.10%), other products (3.23%), instruments (2.81%), and microbiological transport systems (0.12%) [2]. Stock Performance - As of October 21, Yangpu Medical's stock price reached 7.85 CNY per share, with a trading volume of 28.23 million CNY and a turnover rate of 1.34%, resulting in a total market capitalization of 2.43 billion CNY [1]. - The stock has experienced a net inflow of 527,800 CNY from main funds, with large orders accounting for 10.60% of purchases and 8.73% of sales [1]. Financial Performance - For the first half of 2025, Yangpu Medical reported a revenue of 231 million CNY, a year-on-year decrease of 21.22%. However, the net profit attributable to shareholders increased by 389.40% to 15.27 million CNY [2]. - The company has not distributed any dividends in the past three years, with a total payout of 79.13 million CNY since its A-share listing [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 5.76% to 24,400, with an average of 11,149 circulating shares per person, an increase of 11.13% [2]. - Notable institutional holdings include Huaxia CSI 500 Index Enhanced A (007994) as the fifth largest shareholder, increasing its stake by 3.60 million shares, and new entrants such as Huaxia Zhisheng Pioneer Stock (LOF) A (501219) and Huaxia CSI 500 Index Smart Enhanced A (013233) [3].

Group 1 - Yangpu Medical announced the appointment of Zhou Wei as the new deputy general manager, based on the recommendation of the controlling shareholder Zhuhai Gree Financial Investment Management Co., Ltd. and the nomination by the acting general manager Jiang Guangcheng [1] - For the fiscal year 2024, Yangpu Medical's revenue composition is 99.18% from industrial operations and 0.82% from financial leasing [1] - The current market capitalization of Yangpu Medical is 2.4 billion yuan [2] Group 2 - The competition between Farmer and Yibao has intensified, with Farmer's green bottle launch leading to a significant market share decline for Yibao, dropping nearly 5 percentage points [2]

一、审议通过《关于聘任周伟为公司副总经理的议案》 第六届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 阳普医疗科技股份有限公司（以下简称"公司"）第六届董事会第十五次会 议（以下简称"本次会议"）通知已于 2025 年 9 月 22 日以电子邮件方式送达全 体董事。本次会议于 2025 年 9 月 29 日在公司会议室以现场与通讯相结合的方式 召开。本次会议应到董事 9 人，实到董事 9 人，公司监事和高级管理人员列席了 本次会议。本次会议的内容以及召集、召开的方式、程序均符合《公司法》和《公 司章程》的规定。本次会议由董事长杨涛先生主持。与会董事经过充分的讨论， 通过以下决议： 公司董事会同意聘任周伟先生为公司副总经理，任期自本次董事会审议通过 之日起至公司第六届董事会任期届满之日止。 具体内容详见公司同日在中国证监会指定的创业板信息披露网站巨潮资讯网 披露的《关于聘任高级管理人员的公告》（公告编号：2025-043）。 证券代码：300030 证券简称：阳普医疗 公告编号：2025-042 阳普医疗科技股份有限公司 表决结果： ...